According to Oppenheimer, Stereotaxis STXS rating is downgraded to Perform.
Oppenheimer said that it is lowering its rating on STXS to Perform from Outperform and removing its $5 price target. “We lower our '11E/'12E sales by $19M/$18M to 45.2/$62.0M, respectively. Visibility at this point is low. Cost cuts partially offset for '11E/'12E EPS of ($0.61)/($0.31).”
Stereotaxis closed yesterday at $2.85.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsHealth CareHealth Care EquipmentOppenheimer
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in